There are a number of reasons why a person may want to lose weight, including reducing disease risk factors, improving overall quality of life, and managing disease-related symptoms. Even though ...

When combined with diet, exercise and behavioral therapy, orlistat, a drug that decreases fat absorption, appears helpful for improving weight management in obese adolescents, compared with placebo, ...

Orlistat, an antiobesity drug with well-documented efficacy in weight reduction and maintenance, has beneficial effects on metabolic variables. It reduces the incidence of Type 2 diabetes in patients ...

Obesity and dyslipidemia both increase the risk of hyperuricemia. Orlistat, a lipase inhibitor, may lower uric acid levels in patients with obesity, according to new research. Investigators led by ...

OBJECTIVES: This placebo-controlled open study was designed to test the hypothesis that most of the gastrointestinal (GI) side events induced by treatment of obese patients with orlistat (a ...

In a recent study published in The American Journal of Clinical Nutrition, researchers compared the effects of an experimental low-carbohydrate and high-protein diet and orlistat with that of a ...

A team of UK-based investigators explored the long-term cardiovascular outcomes in patients with obesity who were administered orlistat therapy. People with obesity using orlistat for weight loss may ...

Numerous drugs have been tried in the fight against obesity some affect neurons in the brain, others act on the liver, and one (orlistat, sold as Xenical or Alli) acts to decrease the amount of fat ...

Review the side-effects of Orlistat as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Learn everything you need to know about Orlistat-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Blood samples were taken weekly to determine plasma UCB concentration. Mean intra-individual variation in plasma UCB concentrations in the control period before start of treatment was <10% (mean ...

Clin Lipidology. 2009;4(3):331-341. Furthermore, at 6 months significant in-group changes were observed for body weight, BMI and waist circumference in all treatment groups, but these reductions were ...